Drug intelligence / Profile preview

QL-110

Development stage: Preclinical
Lead developer: Shenzhen Qinglan Biotechnology
Modality: Peptides
Administration: Transdermal

Overview

QL-110 is a peptide-based glucagon-like peptide-1 (GLP-1) receptor agonist developed by BioQingLam for the treatment of type 2 diabetes mellitus (T2DM). The drug is formulated as a soluble microneedle patch for transdermal delivery, utilizing BioQingLam's proprietary drug delivery technology platform. This delivery method is designed to provide a non-invasive alternative to subcutaneous injections, potentially improving patient adherence and therapeutic outcomes. QL-110 is currently being evaluated in investigator-initiated trials (IIT) as part of the company's focus on 505(b)(2) or hybrid innovation pathways.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on QL-110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL-110.

Explore the full profile